NCT07301138 2025-12-24
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
Phase 2 Not yet recruiting
Clinical Trials
5 trialsNCT06792253 2025-01-24
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 3 Recruiting
NCT06164327 2023-12-11
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 1 Unknown
NCT06082596 2023-10-13
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
BeBetter Med Inc
Phase 1 Completed
NCT06074107 2023-10-11
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
BeBetter Med Inc
Phase 2 Unknown